Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22767943 | 0.94 | EPHX2 (0.47) | EPHX2CNR2MGLLTRPV1CNR1 | |
| SCHEMBL22767782 | 0.94 | EPHX2 (0.47) | EPHX2CNR2MGLLTRPV1CNR1 | |
| SCHEMBL22767924 | 0.89 | EPHX2 (0.42) | EPHX2CNR2MGLLTRPV1MAPT | |
| SCHEMBL25238770 | 0.89 | SMN1; SMN2 (0.49) | EPHX2CNR2TRPV1 | |
| SCHEMBL22767921 | 0.88 | DRD2 (0.41) | EPHX2CNR2ALDH1A1HPGDMAPT | |
| SCHEMBL25124092 | 0.88 | EPHX2 (0.39) | EPHX2CNR2ALDH1A1HPGDTDP1 | |
| SCHEMBL25124091 | 0.84 | EPHX2 (0.43) | EPHX2ALDH1A1HPGDMAPTTDP1 | |
| SCHEMBL24849910 | 0.82 | DRD2 (0.47) | — | |
| SCHEMBL25124087 | 0.82 | L3MBTL1 (0.42) | TRPV1CNR1ALDH1A1HPGDMEN1 | |
| SCHEMBL22767927 | 0.81 | CNR1 (0.50) | TRPV1CNR1ALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622942-B2 | Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-11 | — | — | US | disclosed |
| US-20200383930-A1 | BENZENE-1,3,5-TRICARBOXAMIDE DERIVED ESTER LIPIDS AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622942-B2 | Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof | LIPA, LIPC, CES1 | EPHX2 324/4885CNR2 124/4885MGLL 56/4885 |
| US-20200383930-A1 | BENZENE-1,3,5-TRICARBOXAMIDE DERIVED ESTER LIPIDS AND USES THEREOF | LIPA, LIPC, CES1 | EPHX2 324/4885CNR2 124/4885MGLL 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.